FibroBiologics Files S-1 for Public Offering

TL;DR

FibroBiologics just filed an S-1, looks like they're gearing up to go public.

AI Summary

FibroBiologics, Inc. filed an S-1 registration statement on June 18, 2024, to register securities under the Securities Act of 1933. The company, incorporated in Delaware with its principal executive offices in Houston, Texas, operates in the Pharmaceutical Preparations sector. This filing indicates the company is preparing to offer its securities to the public.

Why It Matters

This S-1 filing is a crucial step for FibroBiologics, Inc. as it signals their intent to raise capital by selling securities to the public, potentially impacting their growth and market presence.

Risk Assessment

Risk Level: medium — As an S-1 filing, it signifies an early-stage public offering, which inherently carries higher risks compared to established public companies.

Key Numbers

• 333-280303 — SEC File Number (Identifies this specific registration statement with the SEC.)
• 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations.)

Key Players & Entities

• FibroBiologics, Inc. (company) — Registrant
• June 18, 2024 (date) — Filing Date
• Securities Act of 1933 (legal_document) — Governing Act
• Delaware (jurisdiction) — State of Incorporation
• Houston, Texas (location) — Principal Executive Offices
• Pete O’Heeron (person) — Chief Executive Officer
• Brian Fenske (person) — Copies to Counsel
• Norton Rose Fulbright US LLP (company) — Counsel

FAQ

Key Financial Figures

• $6.06 — ave assumed a minimum purchase price of $6.06 per share, as more fully described unde
• $6.73 — ted sales price of our common stock was $6.73 per share. Our founder and Chief Exec

Filing Documents

• forms-1.htm (S-1) — 731KB
• ex5-1.htm (EX-5.1) — 20KB
• ex10-24.htm (EX-10.24) — 18KB
• ex23-2.htm (EX-23.2) — 5KB
• ex107.htm (EX-FILING FEES) — 26KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• ex5-1_002.jpg (GRAPHIC) — 2KB
• formdrs_001.jpg (GRAPHIC) — 4KB
• formdrs_002.jpg (GRAPHIC) — 57KB
• formdrs_003.jpg (GRAPHIC) — 38KB
• formdrs_004.jpg (GRAPHIC) — 34KB
• 0001493152-24-024281.txt ( ) — 993KB

RISK FACTORS

RISK FACTORS 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 13 MARKET AND INDUSTRY DATA 14 TRADEMARKS, SERVICE MARKS AND TRADENAMES 15

USE OF PROCEEDS

USE OF PROCEEDS 15 DIVIDEND POLICY 15 CAPITALIZATION 15 MANAGEMENT 17 PRINCIPAL AND REGISTERED STOCKHOLDERS 24

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 26 SHARES ELIGIBLE FOR FUTURE SALE 30 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 31 PLAN OF DISTRIBUTION 34 LEGAL MATTERS 35 EXPERTS 35 WHERE YOU CAN FIND ADDITIONAL INFORMATION 35 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 35 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor GEM have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor GEM take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. GEM is offering to sell, and seeking offers to buy, shares of our common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor GEM have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by GEM and the distribution of this prospectus outside the United States. i ABOUT THIS PROSPECTUS This prospectus is a part of a registration statement on Form S-1 that we file

Business

Business Update and Recent Developments CYWC628 for Wound Healing: For our Phase 5 pre-clinical study, using a diabetic mouse model (BKS.Cg-Dock7m), we studied the impact of multiple administrations of CYWC628 spheroids and Grafix&trade; on a chemically induced chronic wound often used to mimic diabetic foot ulcers in animal models. The CYWC628 spheroids were administered on Day 0, Day 4, Day 8 and Day 12. The results of our study with this mouse model of a chronic wound indicated (i) a 34.8% reduction in wound area four days after the first administration (day 4) of CYWC628 as compared to 28.6 % for Grafix&trade; (p > 0.05), which was not statistically significant, and 10.2% for the untreated saline control group (p < 0.05); (ii) a 43.4% reduction in wound area four days after the second administration (day 8) of CYWC628 as compared to 37.6 % for Grafix&trade; (p > 0.05), which was not statistically significant, and 21.7% for the untreated saline control group (p < 0.05); (iii) a 69.3% reduction in wound area four days after the third administration (day 12) of CYWC628 as compared to 47.13% for Grafix&trade; (p < 0.05), which was statistically significant, and 36.4% for the untreated saline control group (p < 0.05), which was also statistically significant.; and (iv) an 83.8% reduction in wound area four days after the fourth administration (Day 19) of CYWC628 as compared to 66% for Grafix&trade; (p< 0.05), which was statistically significant, and 55.2% for the untreated saline control group (p<0.01), which was also statistically significant. Grafix&trade; results as compared to saline control were not statistically significant at any of the measured timepoints, whereas CYWC628 as compared to saline control was statistically significant at all measured timepoints. 5 The following graph and chart summarize the results of our Phase 5 pre-clinical study. Effective wound healing is not only determined by the efficiency of wound closure, but also by the quality

View Full Filing

View this S-1 filing on SEC EDGAR